Amended Current Report Filing (8-k/a)
13 Aprile 2021 - 10:09PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
(Amendment
No. 1)
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): April 6, 2021
PULMATRIX,
INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
001-36199
|
|
46-1821392
|
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
99
Hayden Avenue, Suite 390
Lexington,
MA 02421
(Address
of principal executive offices) (Zip Code)
(781)
357-2333
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of exchange on which registered
|
|
Common
Stock, par value $0.0001 per share
|
|
PULM
|
|
The
NASDAQ Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Explanatory
Note
Pulmatrix,
Inc. (the “Company”) filed a Current Report 8-K on April 12, 2021 (the “Original Form 8-K”).
This
Amendment No. 1 on Form 8-K/A is being filed to correct a typographical error in Exhibit 99.2 of the Original Form 8-K. No other
changes have been made to the Original Form 8-K.
Item
8.01. Other Events.
The
Company issued a corrected press release regarding the termination of the License, Development and Commercialization Agreement
by and between Johnson & Johnson Enterprise Innovation, Inc. and the Company on April 12, 2021, which is attached hereto as
Exhibit 99.1. The original press release incorrectly noted that the Company plans to initiate a PUR1800 Phase 2 proof-of-concept
efficacy study for the treatment of AECOPD in 2021. This study is not expected to commence until 2022.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
|
|
PULMATRIX,
INC.
|
|
|
|
|
Date:
April 13, 2021
|
By:
|
/s/
Teofilo Raad
|
|
|
|
Teofilo
Raad
|
|
|
|
Chief
Executive Officer
|
Grafico Azioni Pulmatrix (NASDAQ:PULM)
Storico
Da Mar 2025 a Apr 2025
Grafico Azioni Pulmatrix (NASDAQ:PULM)
Storico
Da Apr 2024 a Apr 2025
